These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 28899020)

  • 1. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
    Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease.
    Ofori E; Pasternak O; Planetta PJ; Li H; Burciu RG; Snyder AF; Lai S; Okun MS; Vaillancourt DE
    Brain; 2015 Aug; 138(Pt 8):2322-31. PubMed ID: 25981960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study.
    Ofori E; Pasternak O; Planetta PJ; Burciu R; Snyder A; Febo M; Golde TE; Okun MS; Vaillancourt DE
    Neurobiol Aging; 2015 Feb; 36(2):1097-104. PubMed ID: 25467638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder.
    Zhou L; Li G; Zhang Y; Zhang M; Chen Z; Zhang L; Wang X; Zhang M; Ye G; Li Y; Chen S; Li B; Wei H; Liu J
    Brain; 2021 Jun; 144(5):1488-1497. PubMed ID: 33880500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal dopaminergic and free-water imaging in Parkinson's disease.
    Yang J; Archer DB; Burciu RG; Müller MLTM; Roy A; Ofori E; Bohnen NI; Albin RL; Vaillancourt DE
    Parkinsonism Relat Disord; 2019 May; 62():10-15. PubMed ID: 30639168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease.
    Guttuso T; Bergsland N; Hagemeier J; Lichter DG; Pasternak O; Zivadinov R
    AJNR Am J Neuroradiol; 2018 Mar; 39(3):479-484. PubMed ID: 29419398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.
    Arribarat G; Pasternak O; De Barros A; Galitzky M; Rascol O; Péran P
    Parkinsonism Relat Disord; 2019 Aug; 65():146-152. PubMed ID: 31182373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study.
    Zhang Y; Wu IW; Tosun D; Foster E; Schuff N;
    PLoS One; 2016; 11(10):e0165540. PubMed ID: 27798653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.